Astria Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Astria Therapeutics şirketinin toplam hissedar öz sermayesi $341.7M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $361.6M ve $20.0M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$344.28m
Eşitlik	US$341.65m
Toplam yükümlülükler	US$19.99m
Toplam varlıklar	US$361.64m

Son finansal sağlık güncellemeleri

Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

Nov 14

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Nov 30

Recent updates

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Nov 27

Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

Nov 14

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Jul 11

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field

Jun 24

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Feb 04

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Dec 10

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Jul 27

We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Apr 03

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Nov 30

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Aug 01

Dr. Chris Morabito is the new medical chief of Astria Therapeutics

Jul 15

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

Jun 30

Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA Capital

Jun 15

Catabasis Pharma shares surge after Quellis Biosciences deal

Jan 29

Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

Dec 10

Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma

Oct 29

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ATXS 'nin kısa vadeli varlıkları ( $351.9M ) kısa vadeli yükümlülüklerini ( $15.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: ATXS şirketinin kısa vadeli varlıkları ( $351.9M ) uzun vadeli yükümlülüklerini ( $4.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ATXS borçsuzdur.

Borcun Azaltılması: ATXS un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ATXS şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: ATXS serbest nakit akışı her yıl % 22.5 2.3 yıl yetecek nakit akışına sahip olacaktır.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/23 12:34
Gün Sonu Hisse Fiyatı	2024/12/20 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Astria Therapeutics, Inc. 11 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Liisa Bayko	Evercore ISI
Joseph Pantginis	H.C. Wainwright & Co.
Carol Werther	H.C. Wainwright & Co.

Astria Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Recent updates

Astria Therapeutics, Inc. Announces Positive Final Results from Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

Astria Therapeutics, Inc. Announces FDA Clearance of IND Application for STAR-0310, a Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

Astria Therapeutics: Transformative Proof Of Concept Data In Hereditary Angioedema

Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth

European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics' Investigational Therapy for the Treatment of Hereditary Angioedema

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Astria Therapeutics: A Cash-Rich Entrant In An Increasingly Crowded Field

Astria Therapeutics, Inc. Appoints Sunil Agarwal to Its Board of Directors

Chief Medical Officer notifies of intention to sell stock

Price target increased by 23% to US$25.57

Astria Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Astria Therapeutics: Too Much Risk, Too Little Reward Despite Near-Term Data Readout

Chief Medical Officer notifies of intention to sell stock

Astria Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.0106 million.

New major risk - Shareholder dilution

Astria Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $125.0106 million.

New minor risk - Share price stability

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

New major risk - Revenue and earnings growth

Price target decreased by 7.0% to US$20.86

Astria Therapeutics, Inc. Presents New Phase 1a Data Confirming Potential for STAR-0125 to Prevent Hereditary Angioedema Attacks with Dosing 2 or 4 Times Per Year at 2023 American College of Allergy, Asthma, and Immunology Annual Scientific Meeting

Astria Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Price target decreased by 8.2% to US$22.43

Astria Therapeutics, Inc. Announces Publication of Star-0215 Preclinical Data in the Journal of Pharmacology and Experimental Therapeutics

We Think Astria Therapeutics (NASDAQ:ATXS) Can Afford To Drive Business Growth

Astria Therapeutics, Inc. Receives Fast Track Designation for Star-0215 for the Treatment of Hereditary Angioedema

Astria Therapeutics, Inc. Appoints John Ruesch as Senior Vice President, Pharmaceutical Sciences and Technical Operations

We're Not Very Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Rate

Astria Therapeutics, Inc. Initiates ALPHA-STAR Phase 1b/2 Clinical Trial of STAR-0215 in People with HAE

Price target increased to US$23.67

Astria Therapeutics, Inc. Announces Positive Preliminary Results from the Phase 1A Clinical Trial of Star-0215 in Healthy Subjects

Here's Why We're Not Too Worried About Astria Therapeutics' (NASDAQ:ATXS) Cash Burn Situation

Insufficient new directors

Astria Therapeutics, Inc. Announces Initiation of A Phase 1A Clinical Trial of STAR-0215 in Healthy Subjects

We're Hopeful That Astria Therapeutics (NASDAQ:ATXS) Will Use Its Cash Wisely

Astria Therapeutics Announces FDA Clearance of IND Application for STAR-0215, a Monoclonal Antibody Inhibitor of Plasma Kallikrein for Treatment of Hereditary Angioedema

Astria Therapeutics, Inc Appoints Chris Morabito as Chief Medical Officer

Dr. Chris Morabito is the new medical chief of Astria Therapeutics

Astria Therapeutics Presents New Preclinical Data of STAR-0215, in Development for Treatment of Hereditary Angioedema

Astria Therapeutics, Inc.(NasdaqGM:ATXS) dropped from Russell Microcap Value Index

Insufficient new directors

Insufficient new directors

Catabasis Pharmaceuticals: Transformation Through Quellis Biosciences Acquisition

Catabasis Pharmaceuticals, Inc.(NasdaqGM:CATB) dropped from Russell 3000E Value Index

Catabasis Pharmaceuticals skyrockets 44% on 7.5% ownership disclosure by RA Capital

Catabasis Pharmaceuticals Provides A Corporate Update

Chief Medical Officer & Senior VP of Clinical Development has left the company

Independent Director has left the company

Catabasis Pharmaceuticals, Inc. Announces Executive Appointments

Catabasis Pharma shares surge after Quellis Biosciences deal

New 90-day high: US$2.75

Will Catabasis Pharmaceuticals (NASDAQ:CATB) Spend Its Cash Wisely?

New 90-day low: US$1.32

Catabasis' Catastrophic Failure, And Other News: The Good, Bad And Ugly Of Biopharma

Catabasis Pharmaceuticals Announces Top-Line Results for the Phase 3 PolarisDMD Trial of Edasalonexent in Duchenne Muscular Dystrophy

New 90-day low: US$5.41

Price target lowered to US$33.00

Catabasis Pharmaceuticals, Inc. Appoints Noah Clauser as Chief Financial Officer

New 90-day high - US$7.55

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri Kaynakları

Analiz Modeli ve Kar Tanesi

Endüstri ve Sektör Metrikleri

Analist Kaynakları